

# SAFETY DATA SHEET

#### SECTION 1: IDENTIFICATION

Tigecycline for Injection, USP Product Name: Manufacturer Name: Fresenius Kabi USA, LLC Three Corporate Drive Lake Zurich, Illinois 60047 Address:

General Phone Number: (847) 550-2300 Customer Service Phone (888) 386-1300

Number:

Health Issues Information: (800) 551-7176 SDS Creation Date: June 07, 2011 October 28, 2016 SDS Revision Date:

#### SECTION 2: HAZARD(S) IDENTIFICATION

GHS Pictograms:





Signal Word: DANGER.

GHS Class: Respiratory sensitisation. Category 1.

Reproductive toxicity. Category 2.
Skin Sensitization. Category 1.
Specific Target Organ Toxicity - STOT, Single Exposure SE. Category 3.
Reproductive toxicity. Effects on or via lactation.

Hazard Statements: May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Suspected of damaging fertility or the unborn child. May cause an allergic skin reaction. May cause respiratory irritation. May cause harm to breast-fed children.

Precautionary Statements:

Obtain special instructions before use. Do not handle until all safety precautions have been read and understood.

Do not breathe dust/fume/gas/mist/vapours/spray. Avoid breathing dust/fume/gas/mist/vapours/spray. Avoid contact during pregnancy and while nursing. Wash hands thoroughly after handling. Do not eat, drink or smoke when using this product.

Do not eat, drink or smoke when using this product.

Use only outdoors or in a well-ventilated area.

Contaminated work clothing should not be allowed out of the workplace.

Wear protective gloves/protective clothing/eye protection/face protection.

In case of inadequate ventilation wear respiratory protection.

IF ON SKIN: Wash with plenty of water.
IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing.

IF exposed or concerned: Get medical advice/attention. Call a POISON CENTER or doctor/physician if you feel unwell.

Specific treatment (see ... on this label).

If skin irritation or rash occurs: Get medical advice/attention.

If experiencing respiratory symptoms: Call a POISON CENTER or doctor/physician.

Take off contaminated clothing and wash it before reuse.

Store in a well-ventilated place. Keep container tightly closed.

Store locked up.

Dispose of contents/container in accordance with Local, State, Federal and Provincial regulations,

Emergency Overview: This product is intended for therapeutic use only when prescribed by a physician. Potential adverse reactions from prescribed doses and overdoses are described in the package insert. Reproductive

Route of Exposure: Inhalation Ingestion Eve contact Skin Absorption, Injection,

Potential Health Effects:

Contact with eyes may cause irritation. Eye:

Skin: May cause skin irritation.

Inhalation: May cause irritation of respiratory tract.

Ingestion: May cause irritation.

Signs/Symptoms: Adverse events from therapeutic doses include: abdominal pain, nausea, vomiting,

diarrhea/constipation blood effects headache hypertension cough increase pain abnormal healing dizziness swelling abscess labored breathing constipation pruritus asthenia/weakness rash hypotension insomnia sweating phlebitis and back pain Occupational exposure has not been fully investigated.

# SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

**Chemical Name** CAS# **Ingredient Percent** EC Num. Sodium Hydroxide 1310-73-2 As needed to adjust pH

Hydrochloric acid 7647-01-0 As needed to adjust pH

Tigecycline 220620-09-7 50 mg/vial

L-Arginine 74-79-3 82.6 mg/vial

#### SECTION 4: FIRST AID MEASURES

Immediately flush eyes with plenty of water for at least 15 to 20 minutes. Ensure adequate flushing of the eyes by separating the eyelids with fingers. Get immediate medical attention. Eve Contact:

Immediately wash skin with plenty of soap and water for 15 to 20 minutes, while removing contaminated clothing and shoes. Get medical attention if irritation develops or persists. Skin Contact:

Inhalation: If inhaled, remove to fresh air. If not breathing, give artificial respiration or give oxygen by trained

If conscious, flush mouth out with water immediately. Call a physician or poison control center immediately. Do not induce vomiting unless directed to do so by medical personnel. Never give Ingestion:

anything by mouth to an unconscious person.

Other First Aid: For Adverse Event Information, please call (800) 551-7176.

#### SECTION 5: FIRE FIGHTING MEASURES

Flash Point: Not established. Flash Point Method: Not established Auto Ignition Temperature: Not established. Lower Flammable/Explosive Limit: Not established. Upper Flammable/Explosive Limit: Not established.

Fire Fighting Instructions: Evacuate area of unprotected personnel. Use cold water spray to cool fire exposed containers to

minimize risk of rupture. Do not enter confined fire space without full protective gear. If possible,

contain fire run-off water.

Extinguishing Media: Use alcohol resistant foam, carbon dioxide, dry chemical, or water fog or spray when fighting fires

Use extinguishing measures that are appropriate to local circumstances and the surrounding

As in any fire, wear Self-Contained Breathing Apparatus (SCBA), MSHA/NIOSH (approved or equivalent) and full protective gear. Protective Equipment:

Hazardous Combustion

Byproducts:

Storage:

Thermal decomposition products may include smoke and toxic fumes. Oxides of carbon, oxides of nitrogen and other organic substances may be formed. Other undetermined low molecular weight hydrocarbon compounds may be released in small quantities depending upon specific conditions of combustion.

# SECTION 6: ACCIDENTAL RELEASE MEASURES

Evacuate area and keep unnecessary and unprotected personnel from entering the spill area. Personal Precautions:

Avoid personal contact and breathing vapors or mists. Use proper personal protective equipment as

Environmental Precautions: Avoid runoff into storm sewers, ditches, and waterways.

Methods for containment: This material will settle out of the air.

Methods for cleanup: Use an industrial vacuum cleaner with a high efficiency filter to clean up dust. Avoid dust generation.

# SECTION 7: HANDLING and STORAGE

When handling pharmaceutical products, avoid all contact and inhalation of vapor, mists and/or fumes. Use with adequate ventilation. Use only in accordance with directions. Handling:

Store at refrigerated temperatures 2 to 8°C (36 to 46°F), [See USP Controlled Room Temperature].

Work Practices: Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety

shower

Hygiene Practices: Wash thoroughly after handling. Avoid contact with eyes and skin. Avoid inhaling vapor or mist.

# SECTION 8: EXPOSURE CONTROLS, PERSONAL PROTECTION

**Engineering Controls:** 

General ventulation is sufficient if this product is being used in a controlled medical setting (clinic, hospital, medical office) for its sole intended parenteral (injection) purpose. Otherwise, use appropriate engineering control such as process enclosures, local exhaust ventilation, or other engineering controls including use of a biosafety cabinet / fume hood to control airborne levels below recommended exposure limits.

Eye/Face Protection: Chemical splash goggles. Wear a face shield also when splash hazard exist. Skin Protection Description: Protective laboratory coat, apron, or disposable garment recommended.

Hand Protection Description: Wear appropriate protective gloves. Consult glove manufacturer's data for permeability data.

Respiratory Protection:

No personal respiratory protective equipment is normally required when this product is being used/administered by a licensed healthcare practitioner (i.e. an end-user such as a clinician / doctor / nurse) for its sole intended parenteral (injection) purpose in a controlled medical setting. The need for respiratory protection will vary according to the airborne concentrations and environmental conditions. A NIOSH approved air-purifying respirator with an organic vapor cartridge or canister may be permissible under certain circumstances. Consult the NIOSH web site

(http://www.cdc.gov/niosh/npptl/topics/respirators/) for a list of respirator types and approved suppliers.

Consult with local procedures for selection, training, inspection and maintenance of the personal Other Protective:

protective equipment.

#### EXPOSURE GUIDELINES

Hydrochloric acid:

Guideline ACGIH: TLV-STEL: 2 ppm(ceiling)

Guideline OSHA: OSHA PEL-STEL 5 ppm Ceiling/Peak

#### SECTION 9: PHYSICAL and CHEMICAL PROPERTIES

Physical State: Powder.

Color: yellow-orange. **Boiling Point:** Not established.

Approximately 256 °C Meltina Point:

Solubility: Freely soluble Vapor Density: Not established. Vapor Pressure: Not established. Percent Volatile: Not established.

Molecular Formula: Mixture Molecular Weight: 585

Flash Point: Not established. Flash Point Method: Not established. Auto Ignition Temperature: Not established.

#### SECTION 10: STABILITY and REACTIVITY

Chemical Stability: Stable under normal temperatures and pressures.

Hazardous Polymerization: Not reported.

Conditions to Avoid: No conditions contributing to instability are known to exist for normal handling of this product.

#### SECTION 11: TOXICOLOGICAL INFORMATION

# Sodium Hydroxide:

RTECS Number: WB490000

Eye: Eye - Rabbit Standard Draize test.: 400 ug Eye - Rabbit Standard Draize test.: 50 ug/24H (RTECS)

Administration onto the skin - Rabbit Standard Draize test.: 500 mg/24H

Ingestion: Oral - Rabbit LDLo: 500 mg/kg [Details of toxic effects not reported other than lethal dose value]

**Hydrochloric acid:** 

Inhalation - Rat LC50: 45000 mg/m3/5M [Lungs, Thorax, or Respiration - Acute pulmonary edema] Inhalation - Rat LC50: 8300 mg/m3/30M [Lungs, Thorax, or Respiration - Acute pulmonary edema] Inhalation: - Mouse LC50: 8300 mg/m3/30M [Lungs, Thorax, or Respiration - Acute pulmonary edema]

(RTECS)

Tigecycline:

RTECS Number: QI7619500 Skin: No data available Inhalation: No data available Ingestion: No data available

Reproductive Toxicity: May cause harm to the unborn child. May cause harm to breastfed babies

<u>L-Arginine</u>:

RTECS Number: CF1934200

Skin: Subcutaneous - Rat TDLo: 349 ug/kg [Behavioral - Analgesia] Intravenous. - Rat TDLo: 0.4 gm/kg [Vascular - BP lowering not characterized in autonomic section Vascular - Measurement of regional blood flow Vascular - Other changes]

Ingestion:

Oral - Rat TDLo: 21 gm/kg/1W (Continuous) [Kidney/Ureter/Bladder - Urine volume increased]
Oral - Rat TDLo: 700 mg/kg/7D (Intermittent) [Liver - Other changes Blood - Changes in serum composition (e.g., TP, bilirubin, cholesterol) Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - Catalases]

# SECTION 12: ECOLOGICAL INFORMATION

Ecotoxicity: No ecotoxicity data was found for the product.

Environmental Stability: No environmental information found for this product.

#### SECTION 13: DISPOSAL CONSIDERATIONS

Waste Disposal: Dispose of in accordance with Local, State, Federal and Provincial regulations.

#### SECTION 14: TRANSPORT INFORMATION

DOT Shipping Name: Not Regulated. DOT UN Number: Not Regulated.

# SECTION 15: REGULATORY INFORMATION

TSCA Inventory Status: Not Listed. Canada DSL: Not Listed.

Sodium Hydroxide:

TSCA Inventory Status: Listed Canada DSL: Listed

**Hydrochloric acid:** 

Canada IDL: Identified under the Canadian Hazardous Products Act Ingredient Disclosure List: 0.1%.845(502)

Tigecycline:

TSCA Inventory Status: Not Listed. Canada DSL: Not Listed.

# SECTION 16: ADDITIONAL INFORMATION

**HMIS Ratings:** 

HMIS Health Hazard: 1 HMIS Fire Hazard: 1 HMIS Reactivity: 1 HMIS Personal Protection: Х

SDS Creation Date: June 07, 2011 SDS Revision Date: October 28, 2016

Disclaimer: The information contained herein pertains to this material. It is the responsibility of each individual

party to determine for themselves the proper means of handling and using these materials based on their purpose and intended use. Fresenius-Kabi assumes no liability resulting from the use of or reliance upon the information contained in this material safety data sheet. This material safety data

sheet does not constitute the guaranty or specifications of the product.

Copyright© 1996-2015 Actio Corporation. All Rights Reserved.